Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PAR-1 contributes to the innate immune response during viral infection
Silvio Antoniak, … , Ursula Rauch, Nigel Mackman
Silvio Antoniak, … , Ursula Rauch, Nigel Mackman
Published February 8, 2013
Citation Information: J Clin Invest. 2013;123(3):1310-1322. https://doi.org/10.1172/JCI66125.
View: Text | PDF
Research Article Immunology

PAR-1 contributes to the innate immune response during viral infection

  • Text
  • PDF
Abstract

Coagulation is a host defense system that limits the spread of pathogens. Coagulation proteases, such as thrombin, also activate cells by cleaving PARs. In this study, we analyzed the role of PAR-1 in coxsackievirus B3–induced (CVB3-induced) myocarditis and influenza A infection. CVB3-infected Par1–/– mice expressed reduced levels of IFN-β and CXCL10 during the early phase of infection compared with Par1+/+ mice that resulted in higher viral loads and cardiac injury at day 8 after infection. Inhibition of either tissue factor or thrombin in WT mice also significantly increased CVB3 levels in the heart and cardiac injury compared with controls. BM transplantation experiments demonstrated that PAR-1 in nonhematopoietic cells protected mice from CVB3 infection. Transgenic mice overexpressing PAR-1 in cardiomyocytes had reduced CVB3-induced myocarditis. We found that cooperative signaling between PAR-1 and TLR3 in mouse cardiac fibroblasts enhanced activation of p38 and induction of IFN-β and CXCL10 expression. Par1–/– mice also had decreased CXCL10 expression and increased viral levels in the lung after influenza A infection compared with Par1+/+ mice. Our results indicate that the tissue factor/thrombin/PAR-1 pathway enhances IFN-β expression and contributes to the innate immune response during single-stranded RNA viral infection.

Authors

Silvio Antoniak, A. Phillip Owens III, Martin Baunacke, Julie C. Williams, Rebecca D. Lee, Alice Weithäuser, Patricia A. Sheridan, Ronny Malz, James P. Luyendyk, Denise A. Esserman, JoAnn Trejo, Daniel Kirchhofer, Burns C. Blaxall, Rafal Pawlinski, Melinda A. Beck, Ursula Rauch, Nigel Mackman

×

Figure 9

Effect of PAR-1 activation on poly I:C activation of STAT1 and CXCL10 expression.

Options: View larger image (or click on image) Download as PowerPoint
Effect of PAR-1 activation on poly I:C activation of STAT1 and CXCL10 ex...
(A) Levels of phosphorylated STAT1 in unstimulated or stimulated (25 μg/ml poly I:C with or without 200 μM agonist peptide for 2 hours) Par1+/+ CFs. STAT1 phosphorylation levels (normalized to GAPDH) are shown relative to unstimulated Par1+/+. (B) STAT1 phosphorylation in Par1+/+ and Par1–/– CFs treated with 125 ng/ml recombinant IFN-β with or without 200 μM agonist peptide for 30 minutes. (C) CXCL10 expression in Par1+/+ (white bars) and Par1–/– (black bars) CFs stimulated with 25 μg/ml poly I:C with or without 200 μM agonist peptide for 8 hours. 10 μM SB203580 was added 30 minutes prior to poly I:C stimulation. (D) Effect of MMP or PAR-1 inhibition during poly I:C stimulation of Par1+/+ CFs. The pan-MMP inhibitor GM6001 (GM; 1 μM), the MMP13 inhibitor WAY170523 (WAY; 1 μM), or the PAR-1 antagonist SCH79797 (SCH; 250 nM) were added 30 minutes prior to poly I:C stimulation. Data (mean ± SEM; n = 3–9 independent experiments) were analyzed by 1-way (A and D) or 2-way (C) ANOVA. *P < 0.05; #P < 0.05 vs. unstimulated control within the same genotype; †P < 0.05 versus poly I:C alone within the same genotype.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts